Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area

Mar 5, 2024 8:30 AM ET

Campaign: Corporate Social Responsibility

" " — Daniel O’Day and a group of Gilead employees visited with San Francisco Community Health Center staff last fall. Image courtesy of San Francisco Business Times.

" " — Gilead employees at a volunteer event for the San Mateo-based Samaritan House. Image courtesy of San Francisco Business Times.

Originally published by SAN FRANCISCO BUSINESS TIMES on bizjournals.com

Much has changed since Daniel O’Day, chairman and CEO, arrived at Gilead Sciences in 2019. The company has grown considerably and expanded on its long-standing leadership in antiviral therapies to include a focus on cancer medicines. Today the Foster City-based company is the second-largest biotech employer in the Bay Area, and according to a Bay Area Council report, it created an estimated economic impact of $22.1 billion in 2020 alone. It has more than 25 marketed therapies for HIV, cancer, hepatitis, COVID-19 and other diseases, and one of the strongest and most diverse pipelines of new medicines in its history.

Continue reading here

Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area

More from Gilead Sciences

Gilead Sciences Publishes 2023 ESG Impact Report

Gilead Sciences Champions Equal Pay

Winn Awards Help Physicians Solve Healthcare Disparities

Gilead Helps Launch Türkiye’s First HIV Testing Week

Gilead Science Supports Increasing Diversity in Clinical Trials: 2024 Toward Health Equity Oncology Grant Supports 36 Global Organizations

Gilead Sciences Aids in Reducing Cancer Care Disparities: Dale Shares Her Breast Cancer Journey and the Power of Information Sharing

Gilead Sciences: National Black HIV/AIDS Awareness Day

Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.